122 related articles for article (PubMed ID: 15120904)
1. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
[TBL] [Abstract][Full Text] [Related]
2. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
[TBL] [Abstract][Full Text] [Related]
3. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
Weyermann J; Lochmann D; Georgens C; Zimmer A
Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antisense oligonucleotide drug delivery systems.
Weyermann J; Lochmann D; Zimmer A
J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506
[TBL] [Abstract][Full Text] [Related]
5. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J
Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers.
Zimmer A
Methods; 1999 Jul; 18(3):286-95, 322. PubMed ID: 10454987
[TBL] [Abstract][Full Text] [Related]
7. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting.
Li FQ; Su H; Wang J; Liu JY; Zhu QG; Fei YB; Pan YH; Hu JH
Int J Pharm; 2008 Feb; 349(1-2):274-82. PubMed ID: 17870261
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation.
Kufleitner J; Worek F; Kreuter J
J Microencapsul; 2010; 27(7):594-601. PubMed ID: 20923399
[TBL] [Abstract][Full Text] [Related]
11. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release.
Kunisawa J; Masuda T; Katayama K; Yoshikawa T; Tsutsumi Y; Akashi M; Mayumi T; Nakagawa S
J Control Release; 2005 Jul; 105(3):344-53. PubMed ID: 15936842
[TBL] [Abstract][Full Text] [Related]
12. Albumin nanoparticles with predictable size by desolvation procedure.
Storp Bv; Engel A; Boeker A; Ploeger M; Langer K
J Microencapsul; 2012; 29(2):138-46. PubMed ID: 22329480
[TBL] [Abstract][Full Text] [Related]
13. The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells.
Taetz S; Nafee N; Beisner J; Piotrowska K; Baldes C; Mürdter TE; Huwer H; Schneider M; Schaefer UF; Klotz U; Lehr CM
Eur J Pharm Biopharm; 2009 Jun; 72(2):358-69. PubMed ID: 18703137
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.
Brzoska M; Langer K; Coester C; Loitsch S; Wagner TO; Mallinckrodt Cv
Biochem Biophys Res Commun; 2004 May; 318(2):562-70. PubMed ID: 15120637
[TBL] [Abstract][Full Text] [Related]
15. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
Anhorn MG; Mahler HC; Langer K
Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
Amidi M; Romeijn SG; Borchard G; Junginger HE; Hennink WE; Jiskoot W
J Control Release; 2006 Mar; 111(1-2):107-16. PubMed ID: 16380189
[TBL] [Abstract][Full Text] [Related]
17. [Study on polymethacrylate nanoparticles as delivery system of antisense oligodeoxynucleotides].
Wang WX; Chen HL; Liang WQ
Yao Xue Xue Bao; 2003 Apr; 38(4):298-301. PubMed ID: 12889133
[TBL] [Abstract][Full Text] [Related]
18. Bioeliminable polymeric nanoparticles for proteic drug delivery.
Chiellini F; Bartoli C; Dinucci D; Piras AM; Anderson R; Croucher T
Int J Pharm; 2007 Oct; 343(1-2):90-7. PubMed ID: 17580105
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological activity of DTPA linked to protein-based drug carrier systems.
Michaelis M; Langer K; Arnold S; Doerr HW; Kreuter J; Cinatl J
Biochem Biophys Res Commun; 2004 Oct; 323(4):1236-40. PubMed ID: 15451429
[TBL] [Abstract][Full Text] [Related]
20. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells.
Azarmi S; Huang Y; Chen H; McQuarrie S; Abrams D; Roa W; Finlay WH; Miller GG; Löbenberg R
J Pharm Pharm Sci; 2006; 9(1):124-32. PubMed ID: 16849014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
